Typically, collaborator data is simply packaged up in a PDF format and sent via email. Job well done, right? Not quite…
96% of pharma executives say their companies have plans to collaborate with strategic partners. And, according to Deloitte, externally developed assets account for over half of their survey respondents’ late stage pipeline; of that co-developed assets account for 30%.
Publicly traded companies that depend on collaboration often emphasize the risk that should “any failure on the part of our collaborator to comply with applicable laws and regulatory requirements… could have an adverse effect on our revenues as well as involve us in possible legal proceedings.”
The current methods of collaboration present the following issues: